MTOR and gastric cancer: Our in vitro study demonstrated that mTOR inhibition may be considered as a potential treatment strategy for trastuzumab-resistant GC, and mTOR inhibitors in combination with trastuzumab may prevent or delay clinical resistance and improve the efficacy of trastuzumab in GC.